Projecting future drug expenditures--2006.
暂无分享,去创建一个
Nilay D Shah | James M Hoffman | N. Shah | J. Hoffman | G. Schumock | L. Vermeulen | R. Hunkler | Lee C Vermeulen | Robert J Hunkler | Karrie M Hontz | Glen T Schumock | Penny Grim | J. M. Hoffman | Penny Grim | N. Shah
[1] Bradley C Strunk,et al. Tracking health care costs: declining growth trend pauses in 2004. , 2005, Health affairs.
[2] I. Melnikova. Future of COX2 inhibitors , 2005, Nature Reviews Drug Discovery.
[3] M. Sipkoff. Biogenerics at the gate waiting for the FDA to act , 2005 .
[4] P. Ubel,et al. Responding to the Immunoglobulin Shortage: A Case Study , 2002, Journal of health politics, policy and law.
[5] K. Aaronson,et al. Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.
[6] E. Topol. Nesiritide - not verified. , 2005, The New England journal of medicine.
[7] K. Aaronson,et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.
[8] The outlook for hospital spending. , 2003, Health affairs.
[9] Subrata Ghosh,et al. Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.
[10] Kathryn A Phillips,et al. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 19972000 , 2005, Annals of Internal Medicine.
[11] H. Büller,et al. Direct thrombin inhibitors. , 2005, The New England journal of medicine.
[12] K. Tyler,et al. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.
[13] "Me-too" products--friend or foe? , 2004, The New England journal of medicine.
[14] S. Keehan,et al. U.S. health spending projections for 2004-2014. , 2005, Health affairs.
[15] P. Rutgeerts,et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.
[16] P. Gavaza,et al. Medication counseling in Zimbabwe. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[17] B. Goldstein,et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] K. Cantwell,et al. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: implications for health-system pharmacy. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[19] S. Atlas,et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.
[20] M. Sipkoff. Generic manufacturers riding a wave of market consolidation , 2005 .
[21] N. Shah,et al. Projecting future drug expenditures--2004. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[22] Nilay D Shah,et al. Projecting future drug expenditures--2005. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[23] M. Ratner. Neuroimaging heats up , 2005, Nature Reviews Drug Discovery.
[24] S. Mayer,et al. Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage , 2007, Stroke.
[25] R David Yost. New economics of the pharmaceutical supply chain. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] B. Wiens,et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Hesselgrave. Helping to manage the high cost of rare diseases. , 2003, Managed care quarterly.
[28] Allen R Dunehew. Changing dynamics in the pharmaceutical supply chain: a GPO perspective. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[29] A. Jemal,et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.
[30] R. Rapp,et al. Price hikes for generic injectable antibiotics. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[31] S. Okie. What ails the FDA? , 2005, The New England journal of medicine.